HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 386 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $32,708,865 | +19.6% | 856,253 | +12.9% | 1.37% | +25.7% |
| Q2 2023 | $27,345,316 | +0.1% | 758,118 | +6.0% | 1.09% | -4.3% |
| Q1 2023 | $27,315,283 | -46.8% | 715,247 | -20.8% | 1.14% | -46.7% |
| Q4 2022 | $51,373,986 | +41.2% | 902,882 | -1.9% | 2.14% | +35.2% |
| Q3 2022 | $36,392,000 | -11.5% | 920,380 | -1.5% | 1.58% | -7.8% |
| Q2 2022 | $41,101,000 | +11.6% | 934,110 | +1.1% | 1.71% | +37.0% |
| Q1 2022 | $36,829,000 | -2.0% | 923,507 | -1.2% | 1.25% | +13.9% |
| Q4 2021 | $37,579,000 | +3.7% | 934,562 | +5.0% | 1.10% | -2.7% |
| Q3 2021 | $36,221,000 | -13.2% | 890,396 | -3.1% | 1.13% | -12.4% |
| Q2 2021 | $41,733,000 | +9.3% | 919,029 | +0.3% | 1.29% | +1.3% |
| Q1 2021 | $38,191,000 | -5.2% | 916,064 | -2.9% | 1.27% | -9.9% |
| Q4 2020 | $40,305,000 | +15.2% | 943,682 | -29.1% | 1.41% | -9.0% |
| Q3 2020 | $34,975,000 | +3.6% | 1,330,847 | +5.7% | 1.55% | -4.6% |
| Q2 2020 | $33,745,000 | +46.8% | 1,258,681 | -1.5% | 1.62% | +9.1% |
| Q1 2020 | $22,981,000 | -1.7% | 1,277,438 | -3.2% | 1.49% | +35.3% |
| Q4 2019 | $23,389,000 | +73.9% | 1,319,176 | +52.1% | 1.10% | +58.0% |
| Q3 2019 | $13,453,000 | -8.6% | 867,396 | +1.3% | 0.70% | -11.8% |
| Q2 2019 | $14,716,000 | -10.4% | 856,563 | -16.1% | 0.79% | -15.3% |
| Q1 2019 | $16,433,000 | +13.6% | 1,020,695 | +3.2% | 0.93% | -11.9% |
| Q4 2018 | $14,468,000 | +4.1% | 988,939 | +29.3% | 1.06% | +32.2% |
| Q3 2018 | $13,902,000 | +12.2% | 765,103 | +4.2% | 0.80% | +1.9% |
| Q2 2018 | $12,391,000 | -13.5% | 734,528 | +0.4% | 0.78% | -18.1% |
| Q1 2018 | $14,332,000 | -5.5% | 731,636 | -2.3% | 0.96% | +0.1% |
| Q4 2017 | $15,171,000 | +6.7% | 748,809 | -8.5% | 0.96% | +8.3% |
| Q3 2017 | $14,217,000 | +96.1% | 818,505 | +44.7% | 0.88% | +80.8% |
| Q2 2017 | $7,250,000 | – | 565,507 | – | 0.49% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |